Healthcare
0
Our $7.7-Trillion Burning Platform: A Stark Moment for U.S. Healthcare
0

Meanwhile, Robert Groves, MD, executive vice president and chief medical officer of Banner | Aetna, described the tremendous advances he and his colleagues ...

0
How Healthcare Professionals Are Shaping Healthcare’s Future through Medical Research Surveys
0

The field of medicine is in a state of constant evolution, with new developments and developments emerging at a rapid pace. Healthcare professionals ...

0
Challenges in Conducting Economic Evaluations for Orphan Drugs in Rare Diseases – Healthcare Economist
0

Why is it so difficult to estimate the value of orphan drugs indicated for the treatment of rare diseases? There are a ...

0
Time is money in drug development – Healthcare Economist
0

Delays in drug approval cost pharmaceutical companies money. These costs include both lost sales and the additional cost if clinical trials need to last ...

0
Recent Medicare attempts to lower drug prices (beyond IRA) – Healthcare Economist
0

Recently, the Inflation Reduction Act (IRA) is receiving a lot of attention, particularly for its provision that allows CMS to begin price negotiations for ...

0
Helping the paralyzed move – Healthcare Economist
0

The technology is amazing. Of The Economist: Fourteen years ago, Melanie Reid, a journalist, fell from a horse ...

0
Gender-Affirming Physical & Mental Healthcare Should be Standard: In Conversation with 2024 ADAA Conference Keynote Alex Keuroghlian, MD, MPH
0

A lot can happen in 10 years. For Alex Keuroghlian, MD, MPH (any pronoun), the last decade has certainly been a busy, productive and significant one, not only ...

0
A primer on brand-name prescription drug contracting – Healthcare Economist
0

The above is the title of a useful manual of Kenney and Keast (2024). Below I summarize some key points. Provide an overview of pharmacy contracts ...

0
Part 3 – Healthcare Economist
0

See my previous posts on negotiating IRA prices in drug selection (Part 1) and sending manufacturer data (Part 2). Today we will talk about the ...

0
Part 1 – Healthcare Economist
0

CMS launched Guidance on Negotiating IRA Prices last week. Below are some highlights on how medications will be selected. What medications are eligible ...

Tools4BLS
Logo
Register New Account
Compare items
  • Total (0)
Compare
0
Shopping cart